The known-unknown: third- and fourth-generation cephalosporins combined with sulbactam | CMAC

The known-unknown: third- and fourth-generation cephalosporins combined with sulbactam

Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1):41-55

​ Stetsiouk O.U., Kovalenko T.N., Andreeva I.V., Belkova Yu.A.
10.36488/cmac.2023.1.41-55
cephalosporins antibiotic resistance infections in hospitalized patients beta-lactamases betalactamase inhibitors sulbactam сefotaxime/sulbactam cefepime/ sulbactam
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1):41-55

Abstract

Despite the presence of more than 100 different antibacterials in the therapeutic arsenal, beta-lactam antibiotics, in general, and the third-generation cephalosporins, in particular, remain the main option for the treatment of the most of infections in inpatients. At the same time, the widespread and oftentimes inappropriate use of the third-generation cephalosporins in Russian hospitals lead to the emergence and spread of antimicroabial resistance. The review covers the problems of antibiotic resistance to cephalosporins due to the production of beta-lactamases, the role of beta-lactamase inhibitors in overcoming this type of resistance, options for combinations of cephalosporins with beta-lactamase inhibitors, in vitro activity of cefotaxime/sulbactam and cefepime/sulbactam, the results of clinical studies, and the role of the above combinations in the treatment of infections in the hospital.

Olga U. Stetsiouk

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Kovalenko T.N.

Smolensk State Medical University, Smolensk, Russia

Irina V. Andreeva

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Belkova Yu.A.

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Stetsiouk O.U., Andreeva I.V. Modern principles of antibacterial therapy of severe and life threatening bacterial infections. Farmateka. 2008;4:1217. Russian.
  • 2. Bush K., Bradford P.A. β-Lactams and β-Lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247. DOI: 10.1101/cshperspect.a025247
  • 3. Bush K. Past and present perspectives on β-lactamases. Antimicrob Agents Chemother. 2018;62(10): e01076-e01018. DOI: 10.1128/AAC.01076-18
  • 4. Kozlov R.S., Stetsiouk O.U., Andreeva I.V. Current trends in antibiotic resistance of nosocomial infection pathogens in the Russian ICU: what's coming next? Intensivnaja terapija. 2007;4:217-227. Russian.
  • 5. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1988;1(1):109-123. DOI: 10.1128/CMR.1.1.109
  • 6. Lee N., Yuen K.-Y., Kumana C.R. Clinical role of betalactam/beta-lactamase inhibitor combinations. Drugs. 2003;63(14):1511-1524. DOI: 10.2165/00003495200363140-00006
  • 7. Tehrani K.H.M.E., Martin N.I. β-lactam/β-lactamase inhibitor combinations: an update. Medchemcomm. 2018;9(9):1439-1456. DOI: 10.1039/c8md00342d
  • 8. Carcione D., Siracusa C., Sulejmani A., Leoni V., Intra J. Old and new beta-lactamase inhibitors: molecular structure, mechanism of action, and clinical use. Antibiotics. 2021;10(8):995. DOI: 10.3390/antibiotics10080995
  • 9. Yahav D., Giske C.G., Grāmatniece A., Abodakpi H., Tam V.H., Leibovici L. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1): e00115-e00120. DOI: 10.1128/CMR.00115-20
  • 10. Stratchounski L., Kozlov R., Reshedko G., Stetsiouk O., Chavrikova E. Antimicrobial resistance patterns among aerobic gram-negative bacilli isolated from patients in intensive care units: results of multicentre study in Russia. Clin Microbiol Infect. 1998;9(4):497-507. DOI: 10.1111/j.1469-0691.1998.tb00404.x
  • 11. Sidorenko S.V., Stratchounski L.S., Akhmedova L.I., Beloborodov V.B., Bogomolova N.S., Bolshakov L.V., et al. Results of a multicenter study of the comparative activity of cefepime and other antibiotics against pathogens of severe hospital infections (MICROMAX program). Antibiotiki i himioterapija. 1999;44(11):7-16. Russian.
  • 12. Reshedko G.K., Ryabkova E.L., Kretchikova O.I., Sukhorukova M.V., Shevchenko O.V., Edelstain M.V., et al. Antimicrobial resistance patterns of gram-negative nosocomial pathogens in Russian ICUs. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2008;10(2):163-179. Russian.
  • 13. Kozlov R.S., Golub A.V. Antimicrobial stewardship as a renascence of the 'golden age’ of antibiotics. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2011;13(4):332-339. Russian.
  • 14. Sukhorukova M.V., Edelstein M.V., Ivanchik N.V., Skleenova E.Yu., Shajdullina E.R., Azyzov I.S., et al. Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: results of multicenter epidemiological study “MARATHON 2015-2016”. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2019;21(2):147-159. Russian. DOI: 10.36488/cmac.2019.2.147-159
  • 15. Zouzov S.A., Petrova М.М., Kretchikova O.I. Etiology and antimicrobial resistance of hospital-acquired and community-acquired intra-abdominal infections in ICUs of two teaching hospitals. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2009;11(4):348-355. Russian.
  • 16. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Edelstein M.V., Shevelev A.N., Grinyov A.V., et al. Current state of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia: «DARMIS» study (2010-2011). Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2012;14(4):280-302. Russian.
  • 17. European Antimicrobial Resistance Collaborators. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis. Lancet Public Health. 2022;7(11):e897-913. DOI: 10.1016/S2468-2667(22)00225-0
  • 18. Safdar N., Maki D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobialresistant S. aureus, Enterococcus, gram-negative bacilli, C. difficile and Candida. Ann Intern Med. 2002;136:834844. DOI: 10.7326/0003-4819-136-11-20020604000013
  • 19. Kachalov V.N., Nguyen H., Balakrishna S., SalazarVizcaya L., Sommerstein R., Kuster S.P., et al. Identifying the drivers of multidrug-resistant Klebsiella pneumoniae at a European level. PLoS Comput Biol. 2021;17(1):e1008446. DOI: 10.1371/journal.pcbi.1008446
  • 20. World Health Organization. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. Geneva: World Health Organization; 2022. 697 p. Available at: www.who.int/publications/i/item/9789240062382. Aссessed March 20, 2023.
  • 21. Zakharenkov I.A., Rachina S.A., Kozlov R.S., Belkova Yu.A. Consumption of systemic antibiotics in the Russian Federation in 2017-2021. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2022;24(3):220-225. Russian. DOI: 10.36488/cmac.2022.3.220-225
  • 22. Kozlov R.S., Stetsiouk O.U., Andreeva I.V. Ceftazidimeavibactam: new rules for the game against multidrugresistant gram-negative bacteria. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2018;20(1):24-34. Russian. DOI: 10.36488/cmac.2018.1.24-34
  • 23. Stetsiouk О.U., Andreeva I.V., Lekmanov А.U., Haykina Е.V. Ceftazidime-avibactam use in children and adolescents. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2021;23(2):173-183. Russian. DOI: 10.36488/cmac.2021.2.173-183
  • 24. Ministry of Health of the Russian Federation. Basic prescribing information of medical product Ceftriaxone/sulbactam. Available at: https://grls.rosminzdrav.ru. Aссessed March 27, 2023. Russian.
  • 25. Yakovlev S.V., Suvorova M.P. Cefotaxime/sulbactam: an important addition to the arsenal of inhibitor-protected betalactam antibiotics. Antibiotiki i himioterapija. 2019;64(34):71-80. Russian. DOI: 10.24411/0235-2990-2019-10019
  • 26. Ministry of Health of the Russian Federation. Basic prescribing information of medical product Sulbactam. Available at: https://grls.rosminzdrav.ru. Aссessed March 27, 2023. Russian.
  • 27. Ministry of Health of the Russian Federation. Package leaflet. Sulbactam-GFC®. Available at: https://grls.rosminzdrav.ru. Aссessed March 27, 2023. Russian.
  • 28. Tamma P.D., Aitken S.L., Bonomo R.A., Mathers A.J., van Duin D., Clancy C.J. Infectious Diseases Society of America. IDSA guidance on the treatment of antimicrobialresistant gram-negative infections, 2022. Version 2.0. Available at: www.idsociety.org/practice-guideline/amrguidance-2.0/#toc-9. Aссessed March 30, 2023.
  • 29. Paul M., Carrara E., Retamar P., Tängdén T., Bitterman R., Bonomo R.A., et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28(4):521-547. DOI: 10.1016/j.cmi.2021.11.025
  • 30. Beloborodov V.B., Goloschapov O.V., Gusarov V.G., Dekhnich А.V., Zamyatin M.N., Zubareva N.A., et al. Guidelines of the Association of AnesthesiologistsIntensivists, the Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and NGO Russian Sepsis Forum "Diagnostics and antimicrobial therapy of the infections caused by multiresistant microorganisms" (update 2022). Vestnik anesteziologii i reanimatologii. 2022;19(2):84-114. Russian. DOI: 10.21292/2078-56582022-19-2-84-114
  • 31. Yokoyama Y., Matsumoto K., Ikawa K., Watanabe E., Morikawa N., Takeda Y. Population pharmacokineticpharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections. J Infect Chemother. 2015;21(4):284-289. DOI: 10.1016/j.jiac.2014.12.005
  • 32. Liu J., Shu Y., Zhu F., Feng B., Zhang Z., Liu L., et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Glob Antimicrob Resist. 2021;24:136-147. DOI: 10.1016/j.jgar.2020.08.021
  • 33. Deng Y., Chen L., Yue M., Huang X., Yang Y., Yu H. Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia. BMC Infect Dis. 2022;22(1):795. DOI: 10.1186/s12879-022-07778-5
  • 34. The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC). In vitro susceptibility of clinical strains of Pseudomonas aeruginosa and Enterobacterales spp., isolated from inpatients in different regions of Russian Federation, to the cefepime and cefotaxime combinations with β-lactamases’ inhibitor sulbactam. Study report. Smolensk. 2019. Russian.
  • 35. Online platform for analysis of AMR data in Russia AMRmap. Available at: https://amrmap.net. Accessed 27 March, 2023.
  • 36. The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC). Clinical recommendations. Susceptibility testing of microorganisms to antimicrobial agents, 2021. Available at: www.antibiotic.ru/files/321/clrec-dsma2021.pdf. Accessed March 18, 2023. Russian.
  • 37. Ministry of Health of the Russian Federation. Clinical guidelines. Community-ascuired pneumonia in adults, 2021. Available at: https://cr.minzdrav.gov.ru/recomend/654_1. Accessed 25 March, 2023. Russian.
  • 38. Report of clinical trial of medicinal product for human use according to the protocol “Open-label randomized comparative study to assess the efficacy and safety of Klaruktam®, powder for solution for injections and infusions 1000 mg + 500 mg (LLC “Ruzpharma”, Russia) and Claforan®, powder for solution for injections and infusions 1 g (“Aventis Pharma Ltd.”, produced by “Patheon UK Ltd.”, GB) in inpatients with community-ascuired pneumonia. Moscow, St. Petersburg, Yaroslavl, 2016. Russian.
  • 39. Pareek A., Kulkarni M., Daga S., Deshpande A., Chandurkar N. Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections. Expert Opin Pharmacother. 2008;9(16):2751-2757. DOI: 10.1517/14656566.9.16.2751
  • 40. Kaur K., Gupta A., Sharma A., Walia G., Singh B., Kaur K. Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection – a prospective comparative study. J Clin Diagn Res. 2014;8(11):HC05-HC8. DOI: 10.7860/JCDR/2014/9742.5090
  • 41. Makwana S.P., Solanki M.N., Dikshit R.K. Cefoperazone + sulbactam versus cefotaxime + sulbactam combination therapy for the treatment of complicated urinary tract infections in hospitalized patients: safety and efficacy analysis. Natl J Physiol Pharm Pharmacol. 2019;9(2):187195. DOI: 10.5455/njppp.2019.9.1236526122018
  • 42. Ministry of Health of the Russian Federation. Basic Prescribing Information of medical product Klaruktam®. Available at: https://grls.rosminzdrav.ru. Aссessed March 27, 2023. Russian.
  • 43. Perepanova T.S., Merenov D.S., Kazachenko A.V., Khazan P.L., Malova Yu.A. Prevention of infectious and inflammatory complications after percutaneous nephrolithotomy. Urologija. 2020;3:26-33. Russian. DOI: 10.18565/urology.2020.3.26-33
  • 44. Ministry of Health of the Russian Federation. Basic Prescribing Information of medical product Maxiktam®-APh. Available at: https://grls.rosminzdrav.ru. Aссessed March 27, 2023. Russian.
  • 45. Zhuravleva M.V., Vasilyuk V.B., Gorelov D.S., Faraponova M.V., Shunkov V.B., Kurnakov A.M., et al. Openlabel, randomised, controlled study to compare the efficacy and safety of cefepime/sulbactam and cefepime in patients with acute pyelonephritis. Сlinical pharmacology and therapy. 2018;5:41-45. Russian. DOI: 10.32756 /0869-5490-2018-5-41-45
  • 46. Yakovlev S.V., Suvorova M.P., Bykov A.O., Zhuravel S.V., Popugaev K.A., Kulagina L.Yu., et al. An open-label, multicenter, observational study of the effectiveness of the cefepime/sulbactam antibiotic (Maxictam®-AF) in patients with intraabdominal infection, nosocomial pneumonia or ventilator-associated pneumonia (Study MAXI-2019). Antibiotiki i himioterapija. 2020;65(11-12):49-58. Russian. DOI: 10.37489/0235-2990-2020-65-11-12-49-58
  • 47. Suvorova M.P., Bykov A.O., Yakovlev S.V., Protsenko D.N., Sychev I.N., Mirzakhamidova S.S., et al. Effectiveness, safety and risk of selection of carbapenem-resistant bacteria in the treatment of severe in-hospital infections with cefepime/sulbactam in comparison with carbapenems. Anaesthesiology and reanimatology. 2020;(3): 59­69. Russian. DOI: 10.17116/anaesthesiology202003159
  • 48. Alekhin A.V., Arutyunov G.P., Bagnenko S.F., Bayalieva A.Z., Zhuravleva M.V., Kaprin A.D., et al. Council of experts resolution on the use of inhibitor-protected beta-lactams in the treatment of community-acquired and nosocomial infections. 11 February, 2019, Moscow. Antibiotiki i himioterapija. 2019;64(1-2):34-36. Russian. DOI: 0.24411/0235-29902019-10006
Views
0 Abstract
0 PDF
0 Crossref citations
Shared